NeuroMetrix (NURO) Reports Q2 Loss of $0.48/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NeuroMetrix Reports Q2 2015 Financial Results and Highlights
July 22, 2015 7:00 AM EDTQuell Commercial Launch Milestone Achieved; Strong Early Shipments
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the Company) (Nasdaq: NURO), today reported financial and business highlights for the quarter ended June 30, 2015.
The Company operates in two primary markets - wearable therapeutic technology and point-of-care tests. Its newest product is Quell, an over-the-counter wearable pain relief device that utilizes proprietary non-invasive neurostimulation technology to provide relief from chronic pain. The device is designed for users with conditions such as diabetic nerve pain, low back and leg pain, fibromyalgia and pain associated with... More
